Expression of Chromosome 21-Localized Genes in Acute Myeloid Leukemia: Differences Between Down Syndrome and Non-Down Syndrome Blast Cells and Relationship to In Vitro Sensitivity to Cytosine Arabinoside and Daunorubicin

• Published in: Blood 1999-08, Vol.94 (4), p.1393-1400
• Main Authors: Taub, Jeffrey W., Huang, Xi, Matherly, Larry H., Stout, Mark L., Buck, Steven A., Massey, Gita V., Becton, David L., Chang, Myron N., Weinstein, Howard J., Ravindranath, Yaddanapudi
• Format: Article
• Language: English
• Subjects: Adolescent; Antibiotics, Antineoplastic - pharmacology; Antibiotics, Antineoplastic - therapeutic use; Antimetabolites, Antineoplastic - pharmacology; Antimetabolites, Antineoplastic - therapeutic use; Antineoplastic agents; Biological and medical sciences; Child; Child, Preschool; Chromosomes, Human, Pair 21; Cytarabine - pharmacology; Cytarabine - therapeutic use; Daunorubicin - pharmacology; Daunorubicin - therapeutic use; Down Syndrome - drug therapy; Down Syndrome - genetics; Down Syndrome - pathology; Drug Resistance, Neoplasm - genetics; Gene Expression Regulation, Neoplastic; General aspects; Humans; Infant; Infant, Newborn; Leukemia, Myeloid - complications; Leukemia, Myeloid - drug therapy; Leukemia, Myeloid - genetics; Leukemia, Myeloid - pathology; Leukocytes - drug effects; Leukocytes - pathology; Medical sciences; Pharmacology. Drug treatments; Tumor Cells, Cultured
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V94.4.1393

The high event-free survival rates of Down syndrome (DS) children with acute myeloid leukemia (AML) are due, in part, to increased in vitro sensitivity of DS myeloblasts to cytosine arabinoside (ara-C) and daunorubicin and the greater generation of ara-C triphosphate (ara-CTP) from ara-C compared with myeloblasts from non-DS patients (Taub et al,Blood 87:3395, 1996). This study further explores the molecular basis of chemotherapy sensitivity of DS AML patients by examining the expression of chromosome 21-localized genes in myeloblasts from newly diagnosed AML patients. Transcript levels of two chromosome 21-localized genes, cystathionine-β-synthase (CBS) and superoxide dismutase (SOD), measured by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR), were 12.0- and 3.8-fold higher in DS compared with non-DS myeloblasts (P < .0001 and P < .0001, respectively). Conversely, there were no significant increases in transcripts for 2 other chromosome 21-localized genes, carbonyl reductase and the reduced folate carrier. CBS transcript levels correlated with both in vitro ara-C sensitivity measured by the 3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyltetrazolium-bromide (MTT) assay (P = .003) and the generation of 3H-ara-C triphosphate (ara-CTP) after in vitro incubations with 5 μmol/L3H-ara-C (P = .0003). Transcripts of deoxycytidine kinase were 2.6-fold higher in DS compared with non-DS cells and may be a factor in the enhanced metabolism of ara-C in DS cells. There was no significant correlation of SOD transcripts with in vitro ara-C and daunorubicin sensitivities. Increased CBS transcripts could result in elevated CBS activity, which modulates ara-C metabolism by altering reduced folate pools, deoxycytidine triphosphate pools, S-adenosylmethionine levels, and/or methylation of the deoxycytidine kinase gene. The further identification of the molecular mechanisms of chemotherapy sensitivity of DS AML patients may lead to significant improvements in the treatment and cure of AML.